Making transplants less toxic – Dr. Rainer Storb and colleagues pioneered the development of a radically different approach to bone marrow transplantation that does not wipe out bone marrow and involves minimal doses of radiation. This non-myeloablative stem cell transplant, or "mini" transplant, is ideal for older patients or those who might not be able to withstand conventional transplants. The procedure does not cause patients to lose their hair or experience severe nausea or other side effects, and can typically be performed without a hospital stay. Learn more >
Improving high-dose chemotherapy – A team led by Dr. William Bensinger has been investigating ways to improve the high-dose chemotherapy that precedes an infusion of the myeloma patient's own stem cells, known as an autologous transplant. One strategy uses a drug called amifostine to shield patients from the damaging effects of melphalan, which is one of the most effective chemotherapeutic drugs for treating myeloma. This technique allows for the patient to receive very high doses of melphalan.
Developing multistep treatments – Research led by Dr. David Maloney has suggested that a multistep treatment approach may be able to improve survival rates for people with multiple myeloma. Maloney's work showed that patients experienced fewer ill effects if they received standard high-dose chemotherapy and a transplant using the patient's own stem cells, followed by a lower-intensity transplant procedure. Learn more >